Here’s our fortnightly wrap of all the news driving ASX health stocks.

The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent.

The biggest news globally was out of US pharma Biogen, which saw its shares soar after announcing the FDA had approved Aducanumab as the first treatment to attack a likely cause of Alzheimer’s.

It was the first Alzheimer’s drug approved by the FDA in almost two decades, but it wasn’t without controversy.

Dementia experts are still debating over whether the clinical trials evidence has proven that the drug works. There is also backlash over Biogen’s decision to price the drug at US$56,000 a year.

Coincidentally, Alzheimer’s is also drawing attention in Australia over the past week.

The share price of ASX-listed Actinogen (ASX:ACW) surged by 70 per cent in a just a fortnight, and was the best healthcare stock performer.

The company had announced the progression of its clinical development program to treat patients with Alzheimer’s disease. It will now commence the first part of the XanaMIA study after receiving approval from the Bellberry Human Research Ethics Committee.

The trial is designed to study improvements in cognitive ability in older volunteers, and patients with mild impairment in the first clinical stage of Alzheimer’s.

In other industry news, American biotechnology company Novavax announced that it will make doses of its coronavirus vaccine here in Australia.

The company revealed that it’s currently searching for an Australian manufacturing partner.

The decision came after the Australian government ordered 51 million doses of Novavax’s coronavirius jabs. The product is still waiting for regulatory clearances in both the US and Australia.

Here’s a table showing how the rest of the ASX-listed healthcare stocks have been performing.

 

Code Company Price % 2 Week return % 1 Yr return Market cap
1AD Adalta Limited 0.16 19 131 $36M
1ST 1St Group Ltd 0.02 0 -46 $8M
4DX 4Dmedical Limited 1.305 13 $257M
AC8 Auscann Grp Hlgs Ltd 0.115 5 -32 $50M
ACR Acrux Limited 0.125 -14 -26 $35M
ACW Actinogen Medical 0.15 70 596 $265M
ADO Anteotech Ltd 0.245 -25 1067 $468M
ADR Adherium Ltd 0.017 0 -37 $38M
AGH Althea Group 0.33 -13 -8 $85M
AHC Austco Healthcare 0.1 4 43 $28M
AHK Ark Mines Limited 0.034 0 0 $1M
ALC Alcidion Group Ltd 0.435 6 149 $445M
ALT Analytica Limited 0.002 0 -33 $8M
AMT Allegra Orthopaedics 0.25 0 108 $26M
ANP Antisense Therapeut. 0.21 0 218 $117M
APH AP Hemp Ltd 0.45 0 309 $34M
ARX Aroa Biosurgery 1.13 -6 $335M
AT1 Atomo Diagnostics 0.16 -6 -52 $69M
ATH Alterity Therap Ltd 0.03 11 76 $62M
ATX Amplia Therapeutics 0.245 9 104 $30M
AVE Avecho Biotech Ltd 0.018 13 100 $32M
BD1 Bard1 Life Sciences 1.76 -21 96 $148M
BIT Biotron Limited 0.051 2 -43 $35M
BNO Bionomics Limited 0.2 5 223 $191M
BOT Botanix Pharma Ltd 0.069 -2 47 $66M
BPH BPH Energy Ltd 0.089 -7 1183 $58M
BWX BWX Limited 5.24 0 31 $723M
BXN Bioxyne Ltd 0.021 11 62 $12M
CAJ Capitol Health 0.35 -3 59 $364M
CAN Cann Group Ltd 0.415 -5 -62 $109M
CBL Control Bionics 0.535 -12 $26M
CDX Cardiex Limited 0.098 36 263 $86M
CDY Cellmid Limited 0.063 5 -63 $11M
CGS Cogstate Ltd 1.35 66 335 $239M
CHM Chimeric Therapeutic 0.305 -3 $59M
CMP Compumedics Limited 0.38 -5 -22 $67M
CPH Creso Pharma Ltd 0.16 19 208 $170M
CTE Cryosite Limited 0.36 3 95 $16M
CYC Cyclopharm Limited 2.78 13 97 $257M
CYP Cynata Therapeutics 0.57 -7 -14 $83M
DOC Doctor Care Anywhere 0.915 -7 $161M
DVL Dorsavi Ltd 0.03 -3 96 $10M
DXB Dimerix Ltd 0.245 11 -43 $48M
EPN Epsilon Healthcare 0.16 3 -60 $29M
EXL Elixinol Wellness 0.14 0 -38 $44M
EYE Nova EYE Medical Ltd 0.31 0 21 $44M
EZZ EZZ Life Science 0.47 0 $5M
FFC Farmaforce Ltd 0.07 8 0 $9M
GLH Global Health Ltd 0.785 2 349 $33M
GSS Genetic Signatures 1.275 15 -42 $177M
GTG Genetic Technologies 0.0085 6 70 $76M
HCT Holista CollTech Ltd 0.063 21 -58 $17M
HXL Hexima 0.155 -9 -49 $18M
IBX Imagion Biosys Ltd 0.115 -12 271 $119M
ICR Intelicare Holdings 0.215 -12 -46 $10M
ICS ICSGlobal Limited 2.17 -2 11 $22M
IDT IDT Australia Ltd 0.29 -12 71 $70M
IHL Incannex Healthcare 0.275 4 429 $296M
ILA Island Pharma 0.35 0 $14M
IMC Immuron Limited 0.16 0 100 $36M
IMM Immutep Ltd 0.635 -5 285 $460M
IMU Imugene Limited 0.32 -32 814 $1579M
IPD Impedimed Limited 0.115 -8 60 $175M
IVX Invion Ltd 0.017 55 113 $88M
JHC Japara Healthcare Lt 1.175 7 108 $319M
JTL Jayex Technology Ltd 0.031 -9 24 $6M
KZA Kazia Therapeutics 1.295 13 211 $167M
LBT LBT Innovations 0.082 -8 -41 $23M
LCT Living Cell Tech. 0.015 36 25 $7M
LSH Lifespot Health Ltd 0.099 4 229 $16M
M7T Mach7 Tech Limited 1.015 -6 36 $247M
MDC Medlab Clinical Ltd 0.18 3 -14 $63M
MDR Medadvisor Limited 0.295 -13 -52 $111M
MEB Medibio Limited 0.008 14 37 $12M
MEM Memphasys Ltd 0.063 -2 9 $47M
MMJ MMJ Group Hlds Ltd 0.085 0 -35 $19M
MVF Monash IVF Group Ltd 0.86 -5 45 $333M
MVP Medical Developments 4.68 -7 -40 $338M
MX1 Micro-X Limited 0.34 0 143 $154M
MXC Mgc Pharmaceuticals 0.048 -2 100 $110M
NC6 Nanollose Limited 0.094 -3 119 $13M
NEU Neuren Pharmaceut. 1.305 5 -20 $151M
NOX Noxopharm Limited 0.7 18 259 $195M
NSB Neuroscientific 0.32 5 83 $45M
NTI Neurotech Intl 0.055 2 817 $38M
NXS Next Science Limited 1.875 4 31 $366M
NYR Nyrada Inc. 0.34 15 94 $35M
OCC Orthocell Limited 0.57 8 61 $109M
OIL Optiscan Imaging 0.29 -21 574 $181M
ONE Oneview Healthcare 0.405 25 935 $175M
ONT 1300 Smiles Limited 6.87 0 31 $162M
OPT Opthea Limited 1.475 1 -56 $514M
OSL Oncosil Medical 0.063 -19 -50 $51M
OSP Osprey Med Inc 0.016 7 14 $41M
OSX Osteopore Limited 0.44 -9 -13 $34M
OVN Oventus Medical Ltd 0.1125 -6 -65 $20M
PAA Pharmaust Limited 0.1 9 -9 $31M
PAB Patrys Limited 0.032 23 115 $59M
PAL Palla Pharma Ltd 0.39 -8 -49 $64M
PAR Paradigm Bio. 2.15 0 -30 $478M
PBP Probiotec Limited 2.11 8 14 $153M
PCK Painchek Ltd 0.068 3 -58 $75M
PGC Paragon Care Limited 0.3 25 100 $104M
PIQ Proteomics Int Lab 1.03 -14 129 $110M
PNV Polynovo Limited 2.68 3 4 $1739M
PSQ Pacific Smiles Grp 2.77 11 79 $442M
PTX Prescient Ltd 0.16 52 142 $86M
PXS Pharmaxis Ltd 0.079 -2 -11 $36M
PYC PYC Therapeutics 0.18 24 106 $554M
RAC Race Oncology Ltd 3.79 20 1066 $530M
RAP Resapp Health Ltd 0.049 -8 -72 $42M
RCE Recce Pharmaceutical 1.065 2 30 $187M
RGS Regeneus Ltd 0.079 -11 7 $24M
RHT Resonance Health 0.18 -8 -5 $87M
RHY Rhythm Biosciences 1.01 -13 1141 $198M
RNO Rhinomed Ltd 0.125 -22 58 $36M
RSH Respiri Limited 0.085 -4 1 $61M
S66 Star Combo 0.235 -8 -50 $31M
SCU Stemcell United Ltd 0.018 6 13 $18M
SDI SDI Limited 0.96 12 30 $114M
SHG Singular Health 0.32 16 $19M
SOM SomnoMed Limited 2.48 10 63 $205M
SUD Suda Pharmaceuticals 0.042 8 18 $16M
TD1 Tali Digital Limited 0.03 -12 -3 $29M
TLX Telix Pharmaceutical 4.61 9 225 $1311M
TRU Truscreen 0.073 0 $26M
UBI Universal Biosensors 0.68 5 224 $120M
VBS Vectus Biosystems 0.93 -5 29 $29M
VHT Volpara Health Tech 1.21 -3 -13 $304M
VLS Vita Life Sciences.. 1.18 17 107 $63M
VTI Vision Tech, Inc 0.013 8 -19 $30M
ZLD Zelira Therapeutics 0.05 11 -19 $59M
ZNO Zoono Group Ltd 0.72 1 -71 $117M
ADO Anteotech 20.5 7.9 95.2 1181.3

 

Cogstate (ASX:CGS) rose by 60 per cent in just one day, on the back of the Biogen news.

Cogstate is partnered with a Japanese pharmaceutical company Eisai, which in turn is a partner of Biogen.

Invion (ASX:IVX) surged by over 50 per cent in the last two weeks, after presenting the initial proof-of-concept testing results on INV-043, the company’s latest Active Pharmaceutical Ingredient (API) using the Photosoft technology.

Key findings from the study indicate that INV-043 has greater anti-cancer activity, and better cancer-targeting characteristics than previous generations of APIs developed by the company.

Noxopharm (ASX:NOX) rose by almost 20 per cent in the last fortnight after reporting that its lead drug, Veyonda, is set to benefit from a Novartis study that reported a median overall survival of 15.3 months for 177Lutetium-PSMA-617, versus 11.3 months for standard care.

That data is significant because Noxopharm’s own recent LuPIN trial data showed even stronger survival outcome when Lutetium-PSMA-617 is combined with Veyonda.

A notable IPO during the week was that of medical and scientific devices company, Trajan Group (ASX:TRJ). The company, which is chaired by former Wallabies rugby captain John Eales, had raised $90 million in the IPO at a price of $1.70 a share, for a $220m market cap. It closed at $1.98 on its first day of trading.